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ABSTRACT
The risk factors and potential practice implications of radiation-induced pleural 
effusion (RIPE) are undefined. This study examined lung cancer patients treated 
with thoracic radiation therapy (TRT) having follow-up computed tomography (CT) 
or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Increased 
volumes of pleural effusion after TRT without evidence of tumor progression was 
considered RIPE. Parameters of lung dose-volume histogram including percent 
volumes irradiated with 5-55 Gy (V5-V55) and mean lung dose (MLD) were analyzed 
by receiver operating characteristic analysis. Clinical and treatment-related risk 
factors were detected by univariate and multivariate analyses. 175 out of 806 
patients receiving TRT with post-treatment imaging were included. 51 patients 
(24.9%) developed RIPE; 40 had symptomatic RIPE including chest pain (47.1%), 
cough (23.5%) and dyspnea (35.3%). Female (OR = 0.380, 95% CI: 0.156–0.926,  
p = 0.033) and Caucasian race (OR = 3.519, 95% CI: 1.327–9.336, p = 0.011) were 
significantly associated with lower risk of RIPE. Stage and concurrent chemotherapy 
had borderline significance (OR = 1.665, p = 0.069 and OR = 2.580, p = 0.080, 
respectively) for RIPE. Patients with RIPE had significantly higher whole lung V5-V40, 
V50 and MLD. V5 remained as a significant predictive factor for RIPE and symptomatic 
RIPE (p = 0.007 and 0.022) after adjusting for race, gender and histology. To include, 
the incidence of RIPE is notable. Whole lung V5 appeared to be the most significant 
independent risk factor for symptomatic RIPE.
INTRODUCTION
Thoracic radiation therapy (TRT) is an important 
component of multi-modality treatment for breast cancer, 
esophageal cancer, and lung cancer including small cell 
and non-small cell lung cancer (NSCLC) [1, 2]. TRT 
can improve survival rates for patients with inoperable 
stage I or II NSCLC [2–4] and limited stage small cell 
lung cancer [5]. TRT is a mainstay treatment in combined 
multi-modalities of surgery and chemotherapy for breast 
cancer, esophagus cancer, and NSCLC [6–9]. Combination 
of targeted therapies including immunotherapies with 
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radiation may also significantly improve patient survival 
in NSCLC [10, 11].
Pulmonary toxicity is a known concern for the 
use of TRT [12–20]. The total dose of radiation, fraction 
sizes, volume of lung exposure, and the concurrence of 
chemotherapeutic treatments have been shown to be 
factors for toxicity to the lung [13, 21, 22]. Radiation-
induced lung injury includes bronchial stenosis, lung 
edema, pleural effusions, fibrosis, and pneumonitis 
[23]. As a late effect after TRT, pleural effusion is often 
induced by inflammation and immune cells such as 
macrophages and CD8+ T cells. Radiation-induced lung 
toxicity (pneumonitis and fibrosis) occurs in 10% to 30% 
of patients following TRT [24, 25]. Interstitial pulmonary 
effects are observed in patients undergoing radiotherapy 
for bone marrow transplantation [26–29]. Previous partial-
volume irradiation parameters were derived from literature 
reviews and the experience of radiation oncologists 
[20, 30]. The tolerance doses (TD) for less than 5% risk 
of lung injury within 5 years of radiation exposure for 1/3, 
2/3 or 3/3 of lung volume were empirically considered 
to be 45, 30, and 17.5 Gy, respectively [20]. Recently, 
dosimetric factors such as V20 and mean lung dose 
have been developed to assess the risk of symptomatic 
radiation-induced lung toxicity (RILT), primarily the 
development of pneumonitis and fibrosis [22, 31, 32]. 
To date, a majority of studies investigating risk 
for lung toxicity in response to radiation have focused 
primarily on development of pneumonitis and fibrosis 
[30]. Pleural effusions are frequent manifestations of a 
variety of systemic and local diseases and are readily and 
frequently detected on chest radiographs. The appearance 
of pleural fluid in vivo depends on chest wall and lung 
elasticity and on pressure relationships. Pleural effusion 
can also develop after radiation damage to the lungs and 
is considered to be one of the most common late toxicities 
after TRT [33–35]. Although pleural effusions have been 
recognized as an adverse effect of radiation exposure for 
over 50 years, the frequency and risk factors have not been 
systematically studied during the last two decades [36]. 
We investigated the rate of thoracic radiation-induced 
pleural effusion (RIPE) and its risk factors for RIPE in 
patients with lung cancer. 
MATERIALS AND METHODS
Patients
Patient eligibility 
Lung cancer patients treated with TRT between 
January 2004 and Dec 2014 from two centers (Augusta 
University and University of Michigan) were reviewed 
retrospectively on the basis of: pathologically confirmed 
non-small cell lung cancer, treatment of thoracic RT ± 
chemotherapy, available computed tomography (CT) scan 
or PET/CT for treatment planning and dosimetric analysis, 
6-month clinical follow-up after RT, with no evidence of 
local disease progression and initial Eastern Cooperative 
Oncology Group performance status (ECOG) ≤ 2. Clinical 
staging was classified according to the American Joint 
Commission on Cancer staging system, 7th edition [37]. 
This research was part of an Institutional Review Board 
approved retrospective study.
Treatment planning and follow-up
Patients were treated with conventionally 
fractionated (1.8 or 2.0 Gy/fraction) using 6-, 10-, or 18-
MV photons. Most patients were treated with ≥ 60 Gy in 
30 fractions over 6 weeks. All patients underwent three-
dimensional conformal radiation therapy (3D-CRT) with 
a CT simulation with a slide thickness of 3.0-5.0 mm. 
The dose-volume histograms (DVH) parameters analyzed 
included mean total lung dose (MLD), and volumes 
of total lung receiving 5 to 55 Gy for each 5 Gy (V5, 
V10, V15, V20, V25, V30, V35, V40, V45, V50, V55, 
respectively). Total lung excluding the main bronchus and 
gross tumor volume was delineated for lung dosimetry 
computation.
Chemotherapy regimens were mainly based on 
carboplatin with paclitaxel, or cisplatin with etoposide. 
Patients were followed per standard of practice. At follow-
up, a history, physical examination, and CT of chest or 
PET-CT were obtained. Chest CT scans and PET/CT 
were reviewed to evaluate RIPE. Adverse events were 
graded retrospectively according to the National Cancer 
Institute-Common Toxicity Criteria Version, version 4.0. 
Symptomatic effusion was defined as effusion ≥ grade 2. 
The following clinical factors were investigated in relation 
to RIPE: age, gender, race, ECOG score, histology, clinical 
stage, smoking status, chemotherapy, and radiation dose. 
Evaluation of pleural effusion
The diagnosis of pleural effusion was independently 
assessed by one physician, and was spot checked by 
another physician. Several previous studies reported 
models based on simple measurement from the chest 
radiographs to estimate the volume of pleural effusions 
[38–41]. Patients with fluid loculation were not excluded. 
We selected the model from Hazlinger, et al. [40], who 
reported the dimension of effusion depth as the best 
planar measurement which was significantly correlated 
with the actual PE. The model described by Hazlinger, 
et al., estimates the PE volumes from CT scans using the 
formula: the volume of PE = 0.365 × b3 – 4.529 × b2 + 
159.723 × b – 88.377, where b was the depth measured 
perpendicularly to the parietal pleura on transversal CT 
scan where the greatest depth was found by scrolling 
through all the images [40]. An example of measurement 
is shown in Figure 1. New pleural effusion or increased 
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volume of PE after TRT without evidence of tumor 
progression was considered to be RIPE. To determine the 
most relevant dose-volume parameter, a receiver operator 
characteristic (ROC) curve was constructed. The Youden 
Index was used as the optimal cutoff from the curve, 
which is defined as sensitivity + specificity-1.
Statistical analysis
Time to RIPE was calculated from the last day of 
TRT to the date at which pleural effusion was observed 
on the follow-up scan. Patients without pleural effusion 
(PE) were censored at the last follow-up or death. The 
overall survival (OS) was defined as the interval between 
the date of treatment initiation and the date of death, or 
time of the last follow-up for patients still alive, which was 
estimated using the Kaplan-Meier method. The logistic 
regression model was used for multivariate analysis. All 
analyses were two-sided and differences were considered 
statistically significant at p < 0.05. Statistical analyses 
were performed employing SPSS, version 19.0 (SPSS Inc, 
Chicago IL).
RESULTS
Patient characteristics
Of 806 patients treated with TRT between 2004 
and 2013, 175 with post-treatment imaging available 
in our electronic medical system and with no evidence 
of thoracic disease progression were included in this 
study. The characteristics of the eligible patients were 
summarized in Table 1. The median OS was 20.5 (range, 
6.37–113.2) months. Concurrent chemotherapy was 
administered to 119 patients. 
Incidence of radiation induced pleural effusion
RIPE of any grade developed in 51 (29.1%) patients, in 
which 39 patients had newly developed PE after TRT without 
disease progression and the remaining 12 patients had PE 
increases after TRT. The median (range) change of PE depth 
was 13.6 (2–90.6) mm, and the median (range) change of 
estimate PE volume was 2164.3 (215.9–248,649) ml. The 
median (range) RIPE interval from end of TRT was 3.7 
(0.6–18.0) months. Forty patients developed symptomatic 
RIPE; 24 of these patients (60.0%) presented with chest 
pain; 12 (30.0%) suffered from cough; and 18 (45.0%) had 
shortness of breath or dyspnea. The actuarial incidence of 
RIPE at 1 and 2 years for those 51 patients was 88.8% and 
11.2%, respectively. The RIPE rates of the two institutions 
in all patients were 22.6% and 38.6% with a borderline 
significance in difference (p = 0.055). 
Risk factor analysis for patient characteristics
The logistic regression analysis of risk factors for 
RIPE is shown in Table 2. In all 175 patients, only gender 
and race were significantly correlated with the occurrence of 
RIPE: Female (OR = 0.380, 95% CI: 0.156–0.926, p = 0.033) 
Figure 1: Example measurement for radiation induced pleural effusion.
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and Caucasian race (OR = 3.519, 95% CI: 1.327–9.336, 
p = 0.011) had lower risk of RIPE. Stage and concurrent 
chemotherapy were correlated with the occurrence of RIPE 
with a borderline significance (OR = 1.665, p = 0.069 for 
advanced stage and OR = 2.580, p = 0.080, for receiving 
concurrent chemotherapy). 
Table 1: Patient characteristics
Characteristics Subgroup No. Patients (%)
Age (years) ≤ 65 98 (56.0)
≥ 65 77 (44.0)
Gender Male 125 (71.4)
Female 50 (28.6)
Race Caucasian 142 (81.1)
African American 33 (18.9)
Histology Squamous cell carcinoma 47 (26.9)
Adenocarcinoma 57 (32.6)
Others 71 (40.5)
Stage I 28 (16.0)
II 32 (18.3)
III 115 (65.7)
Smoking status Non-smoker 16 (9.1)
Former smoker 88 (50.3)
Current smoker 71 (40.6)
Concurrent chemotherapy Yes 119 (68.0)
No 56 (32.0)
Radiation dose (Gy) ≥ 60 123 (70.3)
< 60 52 (29.7)
Baseline demographic and clinical characteristics of the patients at diagnosis.
Table 2: Multivariate analysis of patient characteristics as risk factors
Characteristics OR 95%CI P
Age (years) 1.178 0.528–2.629 0.690
Gender 0.380 0.156–0.926 0.033
Race 3.519 1.327–9.336 0.011
Histology 0.705 0.447–1.112 0.132
Stage 1.665 0.961–2.883 0.069
Smoking status 0.905 0.493–1.664 0.749
Concurrent chemotherapy 2.508 0.897–7.014 0.080
Radiation dose 0.830 0.298–2.314 0.721
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Lung volume exposure correlation with 
development of RIPE
The ROC curve analysis results are shown in 
Figures 2 and 3, and Tables 3 and 4. The whole lung V5, 
V10, V15, V20, V25, V30, V35, V40, V50 and MLD 
were significantly higher in patients with RIPE than 
in those without RIPE (p = 0.007, 0.011, 0.028, 0.047, 
0.038, 0.019, 0.013, 0.034, 0.040 and 0.034), however 
only V5 remained as a significant predictive factor for 
symptomatic RIPE (p = 0.022) after adjusting for race, 
age and histology, with the largest area under the ROC 
curve (AUC = 0.767). For patients with symptomatic 
RIPE, using a cutoff of 41.5% for V5, the sensitivity and 
specificity were 100% and 38.1%, respectively. 
Correlation of RIPE with overall survival
In total, 109 patients died during a median follow 
up of 19.5 months. RIPE was not significantly correlated 
with the overall survival (Figure 3). The median (95% CI) 
overall survival rates for patients with or without RIPE 
were 22.0 (17.8–26.2) and 27.0 (20.4–33.5) months, 
respectively (p = 0.773) (Figure 4).
DISCUSSION 
This study demonstrated that RIPE occurred in 
29.1% of patients treated with TRT. In 80% of patients 
with RIPE, there was an association with significant 
symptoms, such as chest pain and shortness of breath. 
Lung dosimetric factors were significantly greater 
for patients with RIPE, but only V5 was statistically 
significant for symptomatic RIPE in this series. 
Interestingly, Caucasian race and squamous cell tumor 
histology were each associated with a lower risk for RIPE. 
Dose-volume parameters that predict the occurrence 
of RIPE include the dose of radiation and the volume of 
the lung exposed to radiation. Our study indicated that 
although patients with RIPE had exposures from V5-
V55, only V5 was a significant risk factor for RIPE. 
According to the latest National Comprehensive Cancer 
Network guidelines, the limit of lung volume receiving 
more than 20 Gy and 5 Gy (V20 and V5) were 35% 
and 65%, respectively [35]. The data used to generate 
these guidelines were largely obtained from studies of 
symptomatic radiation pneumonitis, and did not take 
into consideration symptomatic RIPE as a late side 
effect. In our current study, we found that < 41.5% could 
be a threshold to avoid a high risk of RIPE, suggesting 
that potential benefit of better treatment plans with 
more stringent limit of V5 to decrease the risk of late 
symptomatic RIPE. Future studies should validate our 
findings by defining pleural surface and generate the 
pleural dosimetry as one of organs at risk for RT planning 
in the clinic and consider RIPE in animal studies.
Our current study found that a significant number 
of patients with pleural effusions also had chest pain, dry 
Figure 2: ROC analysis of various dosimetric factors with RIPE. Definition of abbreviations: ROC = receiver operating 
characteristic curves; RIPE = radiation-induced pleural effusion, Vx = Volume of total lung received more than x Gy.
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cough, and dyspnea, in agreement with previous findings 
[42]. The management of pleural effusions depends 
upon the underlying etiology [42]. When associated with 
disease states, pleural effusions, both benign effusions 
and cancer-associated, are correlated with high mortality 
[43, 44]. Pleural effusions are a significant risk factor for 
the treatment of thoracic cancers [45], and the presence of 
pleural effusions with lung cancer can preclude curative 
surgery [45]. 
This etiology of pleural effusions following radiation 
treatment of thoracic cancers remained to be studied. The 
presence of pleural effusions in malignancy often correlate 
Table 3: Dose-volume histogram and mean lung dose prediction of any radiation-induced pleural 
effusions by ROC and AUC
Variables AUC from ROC SE 95% CI p
V5 0.796 0.086 0.627–0.966 0.007
V10 0.778 0.094 0.593–0.963 0.011
V15 0.741 0.094 0.557–0.924 0.028
V20 0.718 0.095 0.531–0.904 0.047
V25 0.727 0.093 0.544–0.910 0.038
V30 0.757 0.089 0.583–0.931 0.019
V35 0.773 0.085 0.607–0.940 0.013
V40 0.731 0.097 0.542–0.921 0.034
V45 0.704 0.106 0.495–0.912 0.063
V50 0.731 0.098 0.539–0.924 0.034
V55 0.692 0.104 0.489–0.895 0.079
MLD 0.773 0.086 0.604–0.942 0.013
Definition of abbreviations: ROC = receiver operating characteristic curves; AUC = area under the curve; SE = standard 
error of the mean; CI = confidence interval.
Table 4: Dose-volume histogram and mean lung dose prediction of symptomatic radiation-induced 
pleural effusions by ROC and AUC
Variables AUC from ROC SE 95% CI p
V5 0.767 0.085 0.601–0.934 0.022
V10 0.714 0.094 0.530–0.899 0.067
V15 0.635 0.099 0.441–0.828 0.248
V20 0.614 0.100 0.417–0.810 0.331
V25 0.619 0.101 0.422–0.817 0.309
V30 0.640 0.100 0.444–0.837 0.230
V35 0.677 0.097 0.487–0.867 0.129
V40 0.624 0.111 0.407–0.842 0.288
V45 0.593 0.123 0.351–0.834 0.428
V50 0.635 0.114 0.411–0.858 0.248
V55 0.606 0.118 0.375–0.837 0.365
MLD 0.688 0.095 0.510–0.874 0.108
Definition of abbreviations: ROC = receiver operating characteristic curves; AUC = area under the curve; SE = standard 
error of the mean; CI = confidence interval.
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Figure 3: ROC analysis of various dosimetric factors with symptomatic RIPE. Definition of abbreviations: ROC = receiver 
operating characteristic curves; RIPE = radiation-induced pleural effusion.
Figure 4: Kaplan-Meier estimates of OS in 205 patients with  or without RIPE after radiotherapy.  Definition of 
abbreviations: OS = overall survival; RIPE = radiation-induced pleural effusion.
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with changes in the disease course and predict changes 
in responses to cancer therapies [44, 45]. However, both 
non-inflammatory and inflammatory reactions to radiation 
can cause increased fluid in the pleural cavity [42, 46]. 
Normally, the pleural surface is surrounded by ~15 ml 
of acellular, clear fluid that acts as a lubricant for the 
thoracic cavity. Post-RT pleural effusion could also be 
from benign pleural causes such as cardiac, kidney or 
liver failure, infections (such as tuberculosis, pneumonia, 
lung infarcts, lung abscess, and bronchiectasis), systemic 
disorders (such as rheumatoid arthritis, systemic lupus 
erythematosus, uremia, or systemic infections), trauma, or 
radiation therapy. 
The biology or cytopathology of pleural effusions 
following ionizing radiotherapy has also not been 
systematically studied [47]. One study examined specimens 
from 55 irradiated patients with pleural effusions and 
identified bizarre cells, but no other distinctive cytologic 
changes [47]. Increased secretion into the pleural space 
is thought to involve a wide variety of cells, including 
mesothelial, endothelial, myeloid, and lymph cells 
[44]; in the case of malignant pleural effusions (MPEs), 
tumor cells are also thought to contribute significantly 
to secretions [44]. Tumor volumes and tumor metabolic 
activities, as well as the unique tumor secretome have 
been demonstrated to affect MPEs, which are a common 
complication of advanced malignancy [45]. A variety 
of biochemical markers have been identified in MPEs, 
including pH, lactate dehydrogenase, neutrophil-to-
lymphocyte ratio, and the protein surviving, and attempts 
have been made to correlate these factors with patient 
prognosis [45]. Reasons of MPE cannot explain RIPE 
as we only elected those without tumor progression for 
radiation induced toxicity. 
Murine model studies of the effects of thoracic 
irradiation have demonstrated that pleural effusions occur 
in a number of rodent models including rats and some 
strains of mice [35, 48]. Whole thorax irradiation was also 
demonstrated to induce hypoxic respiratory failure, cardiac 
injury, and pleural effusions in Wistar rats [35]. However, 
recent recommendations have been to select murine strains 
that do not exhibit pleural effusions in studies of radiation-
induced lung injury [35, 48]. In light of our current 
finding, the study of murine models that do develop 
RIPE is essential to the understanding of the complexity 
of radiation-induced injuries to the thoracic tissues in 
patients. The use of murine models with RIPE would 
additionally aid in the understanding of the mechanism(s) 
of pleural effusion in response to ionizing radiation as well 
as the identification of cytologic alterations that occur. 
Considering the relative high rate of RIPE and its clinical 
significance, future studies are needed to understand the 
mechanism in both animal models and patients.
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